le-FLU-noe-mide 
Contraindicated in:
Use Cautiously in:
Exercise Extreme Caution in:
CV: chest pain, hypertension.
Derm: alopecia, rash, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), dry skin, eczema, pruritus, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN).
EENT: pharyngitis, rhinitis, sinusitis.
F and E: hypokalemia.
GI: diarrhea, nausea, ↑ liver enzymes, abdominal pain, anorexia, dyspepsia, gastroenteritis, HEPATOTOXICITY, HEPATOTOXICITY, mouth ulcers, vomiting.
Metab: ↓ weight.
MS: arthralgia, back pain, joint disorder, leg cramps, synovitis, tenosynovitis.
Neuro: headache, dizziness, paresthesia, peripheral neuropathy, weakness.
Resp: bronchitis, cough, INTERSTITIAL LUNG DISEASE (ILD), pneumonia.
Misc: INFECTION (INCLUDING SEPSIS AND TUBERCULOSIS [TB] REACTIVATION).
Drug-Drug:
Therapeutic Classification: antirheumatics (DMARDs)
Pharmacologic Classification: immune response modifiers, pyrimidine synthesis inhibitors
Absorption: 80% absorbed following oral administration;.
Distribution: Crosses the placenta.
Protein Binding: 99%.
Metabolism/Excretion: Extensively metabolized in the liver to teriflunomide, which is responsible for pharmacologic activity; metabolites excreted in urine (43%) and feces (48%). Also undergoes biliary recycling.
Half-life: 14–18 days.
(antirheumatic effect)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | 1 mo | 3–6 mo | wk–mos† |
†Due to persistence of active metabolite.
le-FLU-noe-mide
NDC Code*